HRMY vs JPM Stock Comparison
HRMY currently leads JPM in this stock comparison, with AIQ scores of 73 vs 65. The clearest difference is value, while JPM has the stronger risk resilience profile.
What is the main difference between HRMY and JPM?
HRMY leads the current stock comparison as Harmony Biosciences Holdings, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Harmony Biosciences Holdings, Inc. vs JPMorgan Chase & Co.
HRMY leads
HRMY leads by 8 AIQ points, primarily on Value, but the lead has narrowed from 17 points over 30 sessions.
Fragile: 3 of 6 evidence groups support HRMY, its lead is narrowing, and its signal state is cleanly positive.
Harmony Biosciences Holdings, Inc.
JPMorgan Chase & Co.
The Algovestiq AIQ Score currently favors HRMY over JPM, 73 versus 65 as of Nov 15, 2026. HRMY's advantage is driven primarily by stronger value, while JPM holds the stronger risk resilience profile. HRMY also shows the weaker technical structure relative to its 50-day moving average. 3 of 6 covered evidence groups favor HRMY today, and the comparison is rated Fragile on stability: only 3 of 6 covered evidence groups agree. HRMY lead: Weakening — the AIQ differential moved from 17 to 8 points over 30 sessions.
Compare Harmony Biosciences Holdings, Inc. and JPMorgan Chase & Co. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare HRMY and JPM against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value89 vs 10HRMY +79
- Risk Resilience63 vs 87JPM +24
- Quality77 vs 86JPM +9
- Momentum66 vs 70JPM +4
3 of 6 evidence groups favor HRMY. HRMY’s edge is concentrated in value; JPM keeps a meaningful risk resilience edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Quality +1, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 3 active signals are unchanged.
Largest factor move: Momentum +1, not enough on its own to move the overall score.
New signals
- Drawdown Recovery Signal — bullish, risk_regime, long horizon (-9.0%)
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
HRMY's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — HRMY and JPM both carry a full feed there.
The central trade-off
HRMY (Harmony Biosciences Holdings, Inc.): the stronger current systematic profile, led by value.
JPM (JPMorgan Chase & Co.): the counter-case, on risk resilience, quality, momentum.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
HRMYHRMY on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
EvenGrowth figures are not covered for both names.
Value
HRMYHRMY on the peer-relative Value factor, by 79 points.
Momentum
JPMJPM on the Momentum factor, by 4 points.
Lower downside
JPMJPM on Risk Resilience, by 24 points.
Analyst upside
HRMYHRMY on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | HRMY | JPM | Note |
|---|---|---|---|
| Implied upside to target | +52.5% | +7.8% | HRMY has more room |
| Target dispersion | +35% | +30.3% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 12 | 26 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor HRMY. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | HRMY | 73 vs 65 |
| Fundamentals | Even | revenue growth 2.9% vs -7.6%; EPS growth -36.2% vs -27.6%; TTM ROE 4.5% vs 4.1%; gross margin 74% vs 63.2%; operating margin 22.2% vs 28.2% |
| Valuation | HRMY | Value 89 vs 10 |
| Technicals | JPM | Price vs 50-day -12.6% vs 1.7%; vs 200-day -2.4% vs 6.6% |
| Risk Resilience | JPM | Risk Resilience 63 vs 87 |
| Analyst expectations | HRMY | Target upside 52.5% vs 7.8% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of HRMY and JPM and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is moderate at 8 points.
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The leader's signal state is cleanly positive. (supports the conclusion holding)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on HRMY.
How the comparison changed
120 daily snapshots · May 27 – Nov 13HRMY lead: Weakening — the AIQ differential moved from 17 to 8 points over 30 sessions.
- Today
- HRMY +8
- 73 vs 65
- 7 sessions ago
- HRMY +12
- 76 vs 64
- 30 sessions ago
- HRMY +17
- 80 vs 63
- 90 sessions ago
- HRMY +10
- 74 vs 64
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
1 bullish / 0 bearish / 2 neutral
Only HRMY
- ADX Trend Strengthening — neutral, trend, medium horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (4.79%)
6 bullish / 1 bearish / 1 neutral, conflicted
Only JPM
- Bollinger Band Squeeze — neutral, volatility, short horizon (5.9%)
- Drawdown Recovery Signal — bullish, risk_regime, long horizon (-9.0%)
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.65x)
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
- TRIX Bullish Signal — bullish, momentum, short horizon
- Uptrend Structure Active — bullish, trend, long horizon
Both carry 1 more signal that do not separate them: Golden Cross Active.
JPM is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.12%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.98%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1JPM closes the Value gap — currently 79 points behind, the largest single contributor to HRMY's edge.
- 2JPM's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend.
- 3HRMY's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 4The narrowing continues — the lead has already given back 9 points over 30 sessions, and a further 8-point move would eliminate HRMY's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
Split| Metric | HRMY | JPM |
|---|---|---|
| Revenue growth (YoY) | 2.9% | -7.6% |
| EPS growth (YoY) | -36.2% | -27.6% |
| Gross margin | 74% | 63.2% |
| Operating margin | 22.2% | 28.2% |
| Return on equity (TTM) | 4.5% | 4.1% |
| Debt to equity | 0.14 | 3.32 |
Performance
JPM leads 6 of 6 windows| Metric | HRMY | JPM |
|---|---|---|
| 1 week (5 sessions) | 2% | 3.5% |
| 1 month (20 sessions) | -11% | 1.9% |
| 3 months (63 sessions) | -11.5% | -4.1% |
| 6 months (126 sessions) | 12.2% | 16.2% |
| Year to date | -9.8% | 7.4% |
| 1 year (252 sessions) | 0.7% | 8% |
Technicals
JPM has the stronger structure| Metric | HRMY | JPM |
|---|---|---|
| RSI (14) | 36.4 | 56.1 |
| ADX (14) | 34.7 | 18 |
| Price vs 50-day | -12.6% | 1.7% |
| Price vs 200-day | -2.4% | 6.6% |
| Volatility (1M, annualized) | 46.4% | 27.4% |
Risk
JPM is the more resilient| Metric | HRMY | JPM |
|---|---|---|
| Beta | 0.63 | 0.78 |
| Sharpe ratio | 0.07 | 0.44 |
| Sortino ratio | 0.09 | 0.61 |
| Max drawdown | -34.5% | -15.5% |
| Current drawdown | -21.2% | -5.2% |
| Annualized volatility | 40.6% | 22.7% |
| Value at risk (95%) | -3.9% | -2.4% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, HRMY or JPM?
On the Algovestiq AIQ Score, HRMY is the stronger of the two as of Nov 15, 2026, scoring 73 against JPM's 65. The edge comes from value. JPM is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is HRMY or JPM the better buy right now?
HRMY carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 3 of 6 covered evidence groups agree. Treat the lead as provisional.
Why does the AIQ Score favor HRMY over JPM?
The composite weights Quality, Value, Momentum and Risk Resilience. HRMY leads Value by 79 points; JPM leads Risk Resilience by 24 points; JPM leads Quality by 9 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, HRMY or JPM?
Analyst price targets imply +52.5% upside for HRMY and +7.8% for JPM, so the Street currently favors HRMY. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, HRMY or JPM?
HRMY is the better-valued of the two on the peer-relative Value factor. HRMY on the peer-relative Value factor, by 79 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, HRMY or JPM?
Growth figures are not covered for both names. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, HRMY or JPM?
JPM on the Momentum factor, by 4 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, HRMY or JPM?
JPM is the more resilient of the two, so the other name carries the higher downside risk. JPM on Risk Resilience, by 24 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is HRMY more profitable than JPM?
The profitability evidence is mixed: gross margin 74% vs 63.2%; operating margin 22.2% vs 28.2%; ttm roe 4.5% vs 4.1%. Each name leads on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is HRMY's lead over JPM getting stronger or weaker?
HRMY lead: Weakening — the AIQ differential moved from 17 to 8 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.
What would change the HRMY vs JPM verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: JPM closes the Value gap — currently 79 points behind, the largest single contributor to HRMY's edge; JPM's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend; HRMY's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; the narrowing continues — the lead has already given back 9 points over 30 sessions, and a further 8-point move would eliminate HRMY's advantage entirely.
What do the current signals say about HRMY and JPM?
HRMY: 1 bullish / 0 bearish / 2 neutral. JPM: 6 bullish / 1 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on HRMY is Golden Cross Active (bullish, long horizon). On JPM it is Golden Cross Active (bullish, long horizon).
Compare HRMY and JPM with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.